Axerion Therapeutics is a biotech company developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including spinal cord injury and Alzheimer’s disease.
Axerion Therapeutics – prion proteins
Axerion Therapeutics is developing disease-modifying therapeutics for the management and treatment of spinal cord injury (SCI), stroke recovery and Alzheimer’s Disease. Axerion’s proprietary technology platforms include blockers of β-amyloid oligomers binding to Prion Proteins (PrP) on the cell surface of neurons, and Nogo Receptor decoy protein. Indeed, Axerion is developing small molecule oral compounds to block the binding of β-amyloid oligomers to PrP in the brain, thereby preventing a cascade of events that result in brain dysfunction. Thus, Axerion’s technology could help slow or halt cognitive decline in Alzheimer’s patients. Alzheimer’s disease is the most common cause of age-related dementia, affecting more than 25 million people worldwide. And with its Nogo Receptor platform, Axerion is developing treatments that have the potential to stimulate regrowth in axons. The reported prevalence of Spinal Cord Injury is approximately 265.000 chronically injured individuals in the US, and the annual incidence of new cases is 12.000.
Axerion Therapeutics is a private Connecticut-based company developing and commercializing intellectual property licensed from Yale University based on work done in Dr. Stephen Strittmatter’s lab. Board of Directors is composed by David Scheer, Sylvia McBrinn, John Puziss and Russell Tweeddale. Management Team is composed by Amanda Hayward, Eric Frieden and George Maynard.
More about Axerion Therapeutics: www.axeriontherapeutics.com